IL220913A - Puro [2,3– b] pyran derivatives are useful in the synthesis of compounds similar to halochondrine b - Google Patents

Puro [2,3– b] pyran derivatives are useful in the synthesis of compounds similar to halochondrine b

Info

Publication number
IL220913A
IL220913A IL220913A IL22091312A IL220913A IL 220913 A IL220913 A IL 220913A IL 220913 A IL220913 A IL 220913A IL 22091312 A IL22091312 A IL 22091312A IL 220913 A IL220913 A IL 220913A
Authority
IL
Israel
Prior art keywords
halichondrin
furo
analogs
synthesis
derivatives useful
Prior art date
Application number
IL220913A
Other languages
English (en)
Hebrew (he)
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of IL220913A publication Critical patent/IL220913A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/18Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804Compounds having Si-O-C linkages
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/12Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04Ortho-condensed systems
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL220913A 2010-01-26 2012-07-12 Puro [2,3– b] pyran derivatives are useful in the synthesis of compounds similar to halochondrine b IL220913A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29833710P 2010-01-26 2010-01-26
PCT/US2011/022611 WO2011094339A1 (en) 2010-01-26 2011-01-26 Furo [3, 2 -b] pyrane derivatives useful in the synthesis of halichondrin b analogs

Publications (1)

Publication Number Publication Date
IL220913A true IL220913A (en) 2016-11-30

Family

ID=43726543

Family Applications (1)

Application Number Title Priority Date Filing Date
IL220913A IL220913A (en) 2010-01-26 2012-07-12 Puro [2,3– b] pyran derivatives are useful in the synthesis of compounds similar to halochondrine b

Country Status (11)

Country Link
US (6) US8203010B2 (OSRAM)
EP (1) EP2528914B1 (OSRAM)
JP (1) JP5800834B2 (OSRAM)
CN (1) CN102803254B (OSRAM)
BR (1) BR112012018232B8 (OSRAM)
CA (1) CA2787919C (OSRAM)
IL (1) IL220913A (OSRAM)
MX (1) MX2012008510A (OSRAM)
RU (1) RU2579511C2 (OSRAM)
SG (2) SG10201500552PA (OSRAM)
WO (1) WO2011094339A1 (OSRAM)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1087960T3 (da) 1998-06-17 2011-06-14 Eisai R&D Man Co Ltd Makrocykliske analoger og fremgangsmåder til deres anvendelse og fremstilling
US7982060B2 (en) 2004-06-03 2011-07-19 Eisai R&D Management Co., Ltd. Intermediates for the preparation of analogs of Halichondrin B
WO2009046308A1 (en) 2007-10-03 2009-04-09 Eisai R & D Management Co., Ltd. Intermediates and methods for the synthesis of halichondrin b analogs
SG189739A1 (en) 2008-04-04 2013-05-31 Eisai R&D Man Co Ltd Halichondrin b analogs
MY160203A (en) 2009-03-30 2017-02-28 Eisai R&D Man Co Ltd Liposome composition
EP2528914B1 (en) 2010-01-26 2014-06-11 Eisai R&D Management Co., Ltd. Furo[3,2-b]pyrane derivatives useful in the synthesis of halichondrin b analogs
AU2012308184B2 (en) 2011-09-18 2015-08-06 Touch Tunes Music Corporation Digital jukebox device with karaoke and/or photo booth features, and associated methods
EP2928464A1 (en) 2012-12-04 2015-10-14 Eisai R&D Management Co., Ltd. Use of eribulin in the treatment of breast cancer
KR102265952B1 (ko) 2013-06-26 2021-06-16 에자이 알앤드디 매니지먼트 가부시키가이샤 암 치료 병용요법으로서 에리불린 및 렌바티닙의 용도
US9850254B2 (en) 2013-07-03 2017-12-26 Sandoz Ag Synthetic process for preparation of macrocyclic C1-keto analogs of Halichondrin B and intermediates useful therein including intermediates containing-SO2-(p-tolyl) groups
CN103483352A (zh) * 2013-10-18 2014-01-01 李友香 抗肿瘤的药用原料药
JP6625533B2 (ja) 2013-11-04 2019-12-25 エーザイ・アール・アンド・ディー・マネジメント株式会社 ハリコンドリンbの類縁体の合成において有用な大環化反応および中間体
CN105916861B (zh) 2013-12-06 2018-12-14 卫材R&D管理有限公司 可用于合成软海绵素b类似物的方法
SG11201609777SA (en) 2014-05-28 2016-12-29 Eisai R&D Man Co Ltd Use of eribulin in the treatment of cancer
EP3160970A4 (en) 2014-06-30 2017-12-27 President and Fellows of Harvard College Synthesis of halichondrin analogs and uses thereof
CA2978226C (en) 2015-03-04 2025-02-18 Eisai R&D Management Co., Ltd. COMBINATION OF A PD-1 ANTAGONIST AND A VEGFR/FGFR/RET TYROSINE KINASE INHIBITOR TO TREAT CANCER
EP3265122B1 (en) 2015-03-04 2022-05-04 Merck Sharp & Dohme Corp. Combination of pembrolizumab and eribulin for treating triple-negative breast cancer
US10344038B2 (en) 2015-04-30 2019-07-09 President And Fellows Of Harvard College Chromium-mediated coupling and application to the synthesis of halichondrins
RU2739034C2 (ru) * 2015-05-07 2020-12-21 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Реакции макроциклизации и промежуточное соединение и другие фрагменты, полезные в синтезе макролидов галихондринов
CN108601760A (zh) 2016-02-12 2018-09-28 卫材R&D管理有限公司 艾日布林的合成中的中间体及相关的合成方法
SMT202100416T1 (it) 2016-03-02 2021-09-14 Eisai R&D Man Co Ltd Coniugati anticorpo-farmaco a base di eribulina e metodi di uso
JP7015237B2 (ja) 2016-04-28 2022-02-02 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍の成長を抑制する方法
CN114805322B (zh) 2016-06-30 2025-05-30 卫材R&D管理有限公司 可用于合成软海绵素大环内酯类及其类似物的普林斯反应和中间体
KR20190082782A (ko) 2016-10-14 2019-07-10 머크 샤프 앤드 돔 코포레이션 요로상피암을 치료하기 위한 pd-1 길항제 및 에리불린의 조합
JP6978758B2 (ja) 2016-11-11 2021-12-08 プレジデント アンド フェローズ オブ ハーバード カレッジ パラジウム媒介ケトール化
CN108658956B (zh) * 2017-03-28 2021-02-02 上海时莱生物技术有限公司 艾日布林中间体及其制备方法
KR102634732B1 (ko) 2017-04-05 2024-02-13 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 마크로시클릭 화합물 및 그의 용도
US9938288B1 (en) 2017-04-05 2018-04-10 President And Fellows Of Harvard College Macrocyclic compound and uses thereof
CN108948064B (zh) 2017-05-17 2021-02-02 上海时莱生物技术有限公司 一种艾日布林中间体及其制备方法
US11498892B2 (en) 2017-07-06 2022-11-15 President And Fellows Of Harvard College Fe/Cu-mediated ketone synthesis
EP4169924A3 (en) 2017-07-06 2023-07-05 President And Fellows Of Harvard College Synthesis of halichondrins
US20190046513A1 (en) 2017-08-10 2019-02-14 Huya Bioscience International, Llc Combination therapies of hdac inhibitors and tubulin inhibitors
CN117924310A (zh) 2017-11-15 2024-04-26 哈佛大学的校长及成员们 大环化合物及其用途
US11419856B2 (en) 2017-11-20 2022-08-23 Basilea Pharmaceutica International AG Pharmaceutical combinations for use in the treatment of neoplastic diseases
CN118894868A (zh) 2018-01-03 2024-11-05 卫材R&D管理有限公司 可用于合成软海绵素大环内酯及其类似物的普林斯反应和化合物
US12036204B2 (en) 2019-07-26 2024-07-16 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
US11083705B2 (en) 2019-07-26 2021-08-10 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU652180A1 (ru) * 1975-12-16 1979-03-15 Краснодарский политехнический институт 1(Фурил-2,)-2-(2-,, формилфурил-5,, ) этилен или его метильное производное как промежуточный продукт дл синтеза фуран-2,5-дикарбоновой кислоты и способ его получени
US5338865A (en) * 1992-03-12 1994-08-16 President And Fellows Of Harvard College Synthesis of halichondrin B and norhalichondrin B
US5436238A (en) 1992-03-12 1995-07-25 President And Fellows Of Harvard College Halichondrins and related compounds
GB9206244D0 (en) 1992-03-23 1992-05-06 Pharma Mar Sa Cytotoxic compound from a marine sponge
TW255880B (OSRAM) 1992-09-09 1995-09-01 Hoechst Ag
AU4255697A (en) 1996-09-06 1998-03-26 Eli Lilly And Company Catalytic selective sulfonylation process
US6653341B1 (en) 1998-06-17 2003-11-25 Eisai Co., Ltd. Methods and compositions for use in treating cancer
US8097648B2 (en) 1998-06-17 2012-01-17 Eisai R&D Management Co., Ltd. Methods and compositions for use in treating cancer
DK1087960T3 (da) * 1998-06-17 2011-06-14 Eisai R&D Man Co Ltd Makrocykliske analoger og fremgangsmåder til deres anvendelse og fremstilling
CA2822994C (en) * 2004-06-03 2016-09-27 Eisai R&D Management Co., Ltd. Intermediates for the preparation of analogs of halichondrin b
US7982060B2 (en) 2004-06-03 2011-07-19 Eisai R&D Management Co., Ltd. Intermediates for the preparation of analogs of Halichondrin B
US20060045846A1 (en) 2004-08-30 2006-03-02 Horstmann Thomas E Reagents and methods for labeling terminal olefins
US20060154312A1 (en) 2004-12-09 2006-07-13 Sergei Agoulnik Tubulin isotype screening in cancer therapy using halichondrin B analogs
WO2008010776A1 (en) 2006-07-21 2008-01-24 Agency For Science, Technology And Research Aigialomycin d and derivatives thereof and their use in treating cancer or malaria or a microbial infection
WO2009046308A1 (en) 2007-10-03 2009-04-09 Eisai R & D Management Co., Ltd. Intermediates and methods for the synthesis of halichondrin b analogs
BRPI0820519A2 (pt) 2007-11-16 2017-05-23 Eisai R&D Man Co Ltd intermediário para a síntese do análogo de halicondrina b e reação de dessulfonilação usada para o intermediário
SG189739A1 (en) 2008-04-04 2013-05-31 Eisai R&D Man Co Ltd Halichondrin b analogs
EP2528914B1 (en) 2010-01-26 2014-06-11 Eisai R&D Management Co., Ltd. Furo[3,2-b]pyrane derivatives useful in the synthesis of halichondrin b analogs
WO2012147900A1 (en) 2011-04-28 2012-11-01 Eisai R&D Management Co., Ltd. Microreactor process for halichondrin b analog synthesis
US9181152B2 (en) 2011-11-30 2015-11-10 Alphora Research Inc. Process for preparation of (3R)-2,4-di-leaving group-3-methylbut-1-ene
IN2014MN02106A (OSRAM) 2012-03-30 2015-09-11 Alphora Res Inc
US9850254B2 (en) 2013-07-03 2017-12-26 Sandoz Ag Synthetic process for preparation of macrocyclic C1-keto analogs of Halichondrin B and intermediates useful therein including intermediates containing-SO2-(p-tolyl) groups
JP6625533B2 (ja) 2013-11-04 2019-12-25 エーザイ・アール・アンド・ディー・マネジメント株式会社 ハリコンドリンbの類縁体の合成において有用な大環化反応および中間体
CN105916861B (zh) 2013-12-06 2018-12-14 卫材R&D管理有限公司 可用于合成软海绵素b类似物的方法
RU2739034C2 (ru) 2015-05-07 2020-12-21 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Реакции макроциклизации и промежуточное соединение и другие фрагменты, полезные в синтезе макролидов галихондринов
CN108601760A (zh) 2016-02-12 2018-09-28 卫材R&D管理有限公司 艾日布林的合成中的中间体及相关的合成方法
CN114805322B (zh) 2016-06-30 2025-05-30 卫材R&D管理有限公司 可用于合成软海绵素大环内酯类及其类似物的普林斯反应和中间体

Also Published As

Publication number Publication date
CA2787919A1 (en) 2011-08-04
US9856276B2 (en) 2018-01-02
CN102803254A (zh) 2012-11-28
SG10201500552PA (en) 2015-03-30
US20160376294A1 (en) 2016-12-29
EP2528914A1 (en) 2012-12-05
RU2579511C2 (ru) 2016-04-10
MX2012008510A (es) 2012-11-21
US8927597B2 (en) 2015-01-06
SG182612A1 (en) 2012-08-30
US20130123519A1 (en) 2013-05-16
CA2787919C (en) 2018-07-31
RU2012136468A (ru) 2014-03-10
BR112012018232B8 (pt) 2023-01-10
US20110184190A1 (en) 2011-07-28
BR112012018232B1 (pt) 2022-11-29
US10494388B2 (en) 2019-12-03
US20120289718A1 (en) 2012-11-15
US20180162885A1 (en) 2018-06-14
US20150175620A1 (en) 2015-06-25
JP5800834B2 (ja) 2015-10-28
US9382262B2 (en) 2016-07-05
WO2011094339A1 (en) 2011-08-04
EP2528914B1 (en) 2014-06-11
US8203010B2 (en) 2012-06-19
BR112012018232A2 (pt) 2016-02-23
US8350067B2 (en) 2013-01-08
CN102803254B (zh) 2016-09-14
JP2013518116A (ja) 2013-05-20

Similar Documents

Publication Publication Date Title
IL220913A (en) Puro [2,3– b] pyran derivatives are useful in the synthesis of compounds similar to halochondrine b
IL208410A0 (en) Halichondrin b analogs
ZA200904745B (en) Spirocyclic tetronic acid derivatives
ZA201205788B (en) 1,2,4-triazine-4-amine derivatives
IL235819A0 (en) Preparation of pyrrolo[b–3,2]pyridines
ZA201206193B (en) Dihydrofuran derivatives as insecticidal compounds
EP2624698A4 (en) Furo [3,2-D] PYRIMIDINE COMPOUNDS
IL213920A0 (en) 3,3'-spiroindolinone derivatives as anticancer agents
LT3093291T (lt) Dipakeistieji oktahidropirolo [3,4-c]pirolai, kaip oreksino receptoriaus moduliatoriai
IL208278A0 (en) Substituted spirocyclic cyclohexane derivatives
ZA200906585B (en) Spirocyclic cyclohexane derivatives
IL220432A (en) History of theo [b – 3,2] pyridinedione and pharmaceutical preparations containing them
SI2598503T1 (sl) Derivati cis-tetrahidro-spiro(cikloheksan-1,1'-pirido(3,4-b)indol)-4-amina
IL216238A0 (en) 7-aza-spiro[3.5]nonane-7-carboxylate derivatives, preparation thereof, and therapeutic use thereof
ZA201206630B (en) Hetaryl-[1,8]naphthyridine derivatives
PL2812337T3 (pl) Pochodne furo[3,2-b]pirydynowe jako inhibitory tbk1 oraz ikk
WO2011009938A3 (en) Stambomycin and derivatives, their production and their use as drugs
IL229567A0 (en) Benzylidine-2h benzene [b] [4,1]thiazine-3(4h)-converted ones, their derivatives, and their medical uses
ZA201208616B (en) Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations
IL232717B (en) 3-cyanoaryl-h1-pyrrolo[b-3,2]pyridine derivatives
ZA201302112B (en) 1,4-oxazepane derivatives
PL2623503T3 (pl) Pochodne chromenu przydatne w leczeniu chorób wywoływanych przez interakcję TCR z NCK
IL222351A (en) Process for making derivatives 4,1-diethylene-di (3-pyroline) -tetrone
IL225764A0 (en) Diastereo-selective preparation of bi-cyclo[2.2.2]octane-2-one compounds
IL219623A0 (en) [1,5]-diazocin derivatives

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed